CE Information: Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia
Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia
Release date: 1/20/2021
Expiration date: 1/19/2022
Estimated time of completion: 30 minutes
Media: Certified journal article
This activity is intended for hematology/oncology advanced practitioners (physician assistants, nurses, pharmacists) and other healthcare professionals involved in the care of patients with CLL at risk for TLS and neutropenia.
At the conclusion of this activity, participants should be better able to:
Identify patients with chronic lymphocytic leukemia at risk of developing tumor lysis syndrome
Implement appropriate prophylactic measures for patients with chronic lymphocytic leukemia based on risk for the prevention of tumor lysis syndrome
Develop strategies for the early identification, monitoring, and management of patients with chronic lymphocytic leukemia who develop tumor lysis syndrome based on current guidelines
Employ approaches to assess and manage neutropenia in patients with chronic lymphocytic leukemia
Apply effective patient risk-stratification measures for TLS and neutropenia
Amy Goodrich, RN, MSN, CRNP
Johns Hopkins Kimmel Cancer Center
This CME/CPE/CNE/AAPA-certified supplement is provided by AXIS Medical Education.
This educational activity is supported by an educational grant from Sanofi Genzyme.
ACCREDITED CONTINUING EDUCATION
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 1/19/2022. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
AXIS Contact Information
For information about the certification of this activity, please contact AXIS at firstname.lastname@example.org.
There is no fee for this educational activity.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. At the conclusion of your article participation, please visit http://ok.cx/1711CLL Enter Access Code: 1711-CLL
Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be immediately available to you.
Disclosure of Conflict of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty, Amy Goodrich, RN, MSN, CRNP, reported a financial interest/relationship or affiliation in the form of Consultant: Janssen Oncology.
The planners, managers, and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, MPA, PharmD, BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.